GLP-1 receptor agonist initiation and risk of colorectal cancer and colonic polyps
The American Journal of the Medical Sciences · 2026-05 · 371 (5) · 449-459
DOI: 10.1016/j.amjms.2026.02.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of the Medical Sciences, 2026-05. Verfasst von Anwar Alshaakh Moh'd Mari und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Central Florida HCA Florida Healthcare, Greater Orlando, FL, USA; Department of Medicine, University of Central Florida College of Medi…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Colorectal Neoplasms, Colonic Polyps. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Some studies suggested that glucagon-like peptide-1 receptor agonists (GLP-1RA) reduce colorectal cancer (CRC) risk, whereas others suggested that GLP-1RA promote tumorigenesis. This study aimed to examine the association of GLP-1RA with incident CRC and colonic polyps. METHODS: This is a retrospective propensity score (PS)-matched cohort study (years 2006-2021) using a new-user, active comparator design. The study included adults who initiated either GLP-1RA or dipeptidyl peptidase-4 inhibitors (DPP4i), the latter as active comparator. We created PS using 61 variables (main cohort). A second PS-matched cohort excluded patients with colonic polyps at baseline (no-polyp cohort). The primary outcomes were incident CRC and colonic polyps. RESULTS: We matched 86,083 pairs in the main cohort without residual differences. There was no significant difference in CRC incidence between GLP-1RA users (0.2 %) and DPP4i users (0.3 %), odds ratio (OR): 0.99; 95 % confidence interval (95 %CI): 0.84-1.17. However, GLP-1RA users had a higher incidence of colonic polyps (5.9 %) compared to DPP4i users (5.3 %); OR: 1.12 (95 %CI: 1.08-1.17). Results were similar in the no-polyp cohort. CONCLUSIONS: The use of GLP-1RA in patients with DM was not associated with a decreased or increased risk of CRC but was associated with a higher risk of incident colonic polyps compared to DPP-4i use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Central Florida HCA Florida Healthcare, Greater Orlando, FL, USA; Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
- Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA; Section of Endocrinology, Orlando VA Healthcare System, Orlando, FL, USA.
- Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA; Education Services, Orlando VA Healthcare System, Orlando, FL, USA. Electronic address: Ishak.mansi@va.gov.
Zitieren
APA
Moh'd Mari, A. A., Alamin, F., Le, M. A., Rizvi, A., & Mansi, I. A. (2026). GLP-1 receptor agonist initiation and risk of colorectal cancer and colonic polyps. The American Journal of the Medical Sciences, 371(5), 449-459. https://doi.org/10.1016/j.amjms.2026.02.002
Vancouver
Moh'd Mari AA, Alamin F, Le MA, Rizvi A, Mansi IA. GLP-1 receptor agonist initiation and risk of colorectal cancer and colonic polyps. The American Journal of the Medical Sciences. 2026;371(5):449-459. doi:10.1016/j.amjms.2026.02.002
BibTeX
@article{MohdMari2026,
author = {Moh'd Mari, Anwar Alshaakh and Alamin, Faris and Le, Minh Anh and Rizvi, Ali and Mansi, Ishak A},
title = {GLP-1 receptor agonist initiation and risk of colorectal cancer and colonic polyps},
journal = {The American Journal of the Medical Sciences},
year = {2026},
volume = {371},
number = {5},
pages = {449--459},
doi = {10.1016/j.amjms.2026.02.002}
}
EUVIMED